High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients.

The Oncologist
Chandra BartholomeuszGabriel N Hortobagyi

Abstract

The mitogen-activated protein kinase (MAPK) signaling pathway is known to be activated in triple-negative breast cancer (TNBC). Extracellular signal-related kinase (ERK), a member of the MAPK pathway, promotes cell proliferation, angiogenesis, cell differentiation, and cell survival. To assess the prognostic impact of ERK in TNBC patients, relative quantities of ERK (ERK-2 and pMAPK) and direct targets of the ERK pathway (MAPK/ERK kinase 1, phospho-enriched protein in astrocytes [PEA]-15, phosphorylated (p)PEA-15, tuberous sclerosis protein 2, p70S6 kinase, and p27) were measured using reverse-phase protein arrays in tumor tissue from patients with TNBC (n = 97) and non-TNBC (n = 223). Protein levels in patients with TNBC were correlated with clinical and tumor characteristics and outcome. The median age of patients with TNBC was 55 years (range, 27-86 years). Disease stage was I in 21%, II in 60%, and III in 20% of the patients. In a multivariate analysis, among patients with TNBC, those with ERK-2-overexpressing tumors had a lower overall survival rate than those with low ERK-2-expressing tumors (hazard ratio [HR], 2.76; 95% confidence interval [CI], 1.19-6.41). However, high pMAPK levels were associated with a significantly ...Continue Reading

References

Dec 16, 1998·The Journal of Biological Chemistry·J W RamosM H Ginsberg
Aug 24, 2000·International Journal of Cancer. Journal International Du Cancer·H MuellerU Eppenberger
Oct 20, 2000·The Journal of Biological Chemistry·J P MacKeiganJ P Ting
Nov 13, 2001·Developmental Cell·E FormstecherH Chneiweiss
Jun 17, 2003·Molecular and Cellular Biology·Alessandra TrenciaFrancesco Beguinot
Sep 25, 2003·The Journal of Biological Chemistry·Fan-Li ChouMark H Ginsberg
Jan 7, 2004·The Journal of Biological Chemistry·Angelique W WhitehurstMelanie H Cobb
Oct 1, 2004·Nature·Philip StephensMichael R Stratton
Sep 26, 2007·Cancer Science·Shinobu UmemuraYutaka Tokuda
Nov 17, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y EralpE Topuz
May 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emad A RakhaIan O Ellis
Jan 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B CorkeryN O'Donovan
Feb 19, 2009·British Journal of Cancer·T MurayamaK Sugihara
Mar 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana M Gonzalez-AnguloBryan T Hennessy
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chandra BartholomeuszNaoto T Ueno

❮ Previous
Next ❯

Citations

Mar 6, 2013·Nature Reviews. Clinical Oncology·Dimitrios ZardavasMartine Piccart
Apr 30, 2014·BMC Genomics·Rendong YangTianwei Yu
Apr 23, 2015·International Journal of Oncology·Yan LiuQifeng Yang
Mar 25, 2014·Pharmacology & Therapeutics·Fiona H Greig, Graeme F Nixon
Nov 6, 2015·Trends in Pharmacological Sciences·Murugan KalimuthoKum Kum Khanna
Oct 27, 2015·Future Medicinal Chemistry·Nelly Fosu-MensahAndrew D Westwell
May 7, 2015·Cancer Treatment Reviews·Aristomenis AnestisAthanasios G Papavassiliou
Apr 9, 2015·Genome Biology·Andrés Castellanos-MartínJesús Pérez-Losada
Apr 12, 2017·Expert Opinion on Therapeutic Targets·Francesca FioryFrancesco Beguinot
May 28, 2019·Journal of Experimental & Clinical Cancer Research : CR·Zilong YanMasafumi Nakamura
Oct 3, 2017·Laboratory Investigation; a Journal of Technical Methods and Pathology·Imran Khan, Patricia S Steeg
Apr 1, 2020·Cancer Biomarkers : Section a of Disease Markers·Yanshi LiGuohua Hu
May 24, 2020·Scientific Reports·Maria GagliardiChandra Bartholomeusz
Feb 8, 2019·Proceedings of the National Academy of Sciences of the United States of America·Sejeong ShinSang-Oh Yoon
Dec 3, 2017·Archives of Pharmacal Research·Sunam ManderJong-Ik Hwang
Aug 28, 2020·Frontiers in Cell and Developmental Biology·Wenjian ChenJun Sun
Nov 29, 2020·Journal of Experimental & Clinical Cancer Research : CR·Shuang WangBei Lin
May 4, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angie M Torres-AdornoNaoto T Ueno
Apr 10, 2015·Cancer Research·Reetta VirtakoivuJohanna Ivaska
Jan 24, 2021·Diabetology & Metabolic Syndrome·Kartika W Taroeno-HariadiTeguh Aryandono
Dec 31, 2020·International Journal of Molecular Sciences·Ha Thi Thu Do, Jungsook Cho
Nov 10, 2018·Matrix Biology : Journal of the International Society for Matrix Biology·R MalikE Cukierman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Rebecca DentSteven A Narod
JAMA : the Journal of the American Medical Association
Lisa CareyRobert C Millikan
© 2021 Meta ULC. All rights reserved